Kalbe Farma stock gets an IDR 500 billion buyback plan for 2026

Published on 10/06/2026 at 10:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kalbe Farma stock is tied to an IDR 500 billion buyback announced for September 17 to December 17, 2026. First-half revenue rose 14.04 percent, but profit fell 2.8 percent.

Kalbe Farma, ID1000125107, Illustration mit AI erstellt.

Kalbe Farma (ISIN ID1000125107) was last at IDR 755 on the Jakarta Stock Exchange on October 6, 2026 at 3:10 p.m. WIB, up IDR 5 or 0.67 percent from the prior close. The key corporate event is a planned IDR 500 billion buyback, which Investor Daily reported on September 16, 2026, with the transaction scheduled to run through December 17, 2026.

Buyback sets the immediate frame

Kalbe Farma plans to use internal funds for the repurchase, while management estimates an IDR 8.4 billion reduction in interest income after the program. The company expects the smaller share count to lift pro forma earnings per share to IDR 81.44, compared with IDR 80.51 for fiscal year 2025, according to Investor Daily.

The buyback arrives while Kalbe is managing a tougher cost base. In a September 11, 2026 report, Kontan said imported raw materials and currency volatility were keeping pressure on margins into the second half of 2026.

Revenue growth meets profit pressure

Kalbe Farma reported IDR 19.47 trillion in first-half 2026 sales, up 14.04 percent from IDR 17.07 trillion in the same period of 2025. Net income attributable to parent shareholders fell 2.8 percent to IDR 1.91 trillion from IDR 1.97 trillion, figures reported by Liputan6 for the period ended June 30, 2026.

The contrast is important for investors: sales expanded by IDR 2.40 trillion year over year, but earnings moved lower as costs grew faster. Kontan reported a 37.6 percent gross profit margin for the first half, down 220 basis points from the prior-year period.

Analysts see room above IDR 755

Investing.com lists a Strong Buy consensus from 17 analysts, including 15 Buy ratings and 2 Hold ratings. Its average 12-month price target is IDR 1,131, with a high of IDR 1,700 and a low of IDR 820; the average target lies 49.8 percent above the October 6 price of IDR 755.

That target spread leaves the margin question central to the stock story. Kalbe is pairing capital-return support with selective pricing, portfolio changes and cost control while first-half sales growth has yet to translate into higher profit.

Kalbe Farma stock stays below its yearly high

Kalbe Farma stock was last at IDR 755 on the Jakarta Stock Exchange on October 6, 2026 at 3:10 p.m. WIB. The session range was IDR 745 to IDR 765, the 52-week range was IDR 630 to IDR 1,345, volume was 22,855,600 shares and market capitalization was IDR 34.2 trillion.